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Summary
Ovarian cancer is  one of the deadliest  diseases plaguing women today. Morbidity and
mortality is drastically high and unfortunately still growing. In many cases, the medicine is
powerless.  The  very  term  cancer  awakens  in  us  the  fear,  uncertainty  and  significantly
increases the level of stress. The disease is an element of human life, it is a drama for the
patient and his family. For a time, completely changes the man and his subordinates pobytom
life in the hospital and the next stages of therapy.
The aim of this work is to present the problems associated with the occurrence of ovarian
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tumors. Presentation of ways of early diagnosis which can significantly increase the survival
rate of women suffering.
The work shows how serious problem in modern gynecological oncology is constantly
ovarian cancer. It is characterized by very high mortality rate among cancers of the female
genital.
Admission
Ovarian  cancer  is  one  of  the  deadliest  diseases  plaguing  women  today.  Morbidity  and
mortality is drastically high and unfortunately still growing. In many cases, the medicine is
powerless.  The  very  term  cancer  awakens  in  us  the  fear,  uncertainty  and  significantly
increases the level of stress. The disease is an element of human life, it is a drama for the
patient and his family. For a time, completely changes the man and his subordinates stays life
in the hospital and the next stages of therapy.
It  would  seem  that  the  widely  propagated  health  promotion  programs,  easier  access  to
specialists, properly maintained and constantly improved procedure and a special vigilance
oncology, became a way to increase the detection of early forms of cancer. Unfortunately, it
does not happen in the case of ovarian cancer.
S cancer, is still a very big problem in modern gynecology oncology. Unfortunately, it is most
often  diagnosed  when  advancement  is  already  very  large.  Most  patients  report  to  the
gynecologist in the III and IV clinical stage FIGO [International Federation of Gynecology
and Obstetrics - The International Federation of Gynecology and Obstetrics].
Symptoms associated with ovarian cancer suggests the disease this organ. They are felt as
symptoms suggestive of gastrointestinal disease.
Morbidity  affects  women  of  all  ages.  Increases  around  the  age  of  menopause  and,
unfortunately sick children as well.
It is believed that the formation of ovarian tumors affecting hormonal factors, genetic and
environmental factors. The incidence is higher in industrialized regions. They fall ill more
often women who have not given birth or not breastfeed. To risk group also includes those
who have had a family history of this disease. Which carry a mutation gene.
Less likely to get sick women who used hormonal contraception.
Ovarian cancer is recognized late, due to the lack of early detection programs. Continuous
development of modern medicine allows the use of different diagnostic methods, but still the
diagnosis comes too late.
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Patients suspected of occurrence of ovarian cancer are performed ultrasound and radiology.
Among laboratory tests should determine the picture of peripheral blood, for the exponents of
liver function and kidney function. It has important diagnostic markers of cancer in blood
serum. Their concentration increases in tumor processes.
Preventive measures are a major issue. The establishment of such AND SOFTWARE could
significantly speed up the detection of ovarian cancer within.
The basic form of screening, regular gynecological check-ups. Two-hand examination of the
vagina  and rectum,  and transvaginal  ultrasound.  Patients  in  whom ovarian  cancer  family
occurred should be tested for the carriers of mutations in the BRCA1 gene (breast cancer 1)
and BRCA2 (breast cancer gene 2).
The importance of early cancer detection and appropriate treatment in these cases. Treatment
requires teamwork, and especially diagnostic and individualization - therapeutic. Negotiations
are always very different and largely depend precisely on the tumor stage.
The aim of this work is to present the problems associated with the occurrence of ovarian
tumors. Presenting ways of early diagnosis which can significantly increase the survival rate
of women.
Epidemiology of ovarian tumors
In  the  modern  world  constantly  ovarian  cancer  is  a  very  big  problem  public.  In  highly
developed  countries  is  continuously  saddled  with  one  of  the  greatest  mortality  among
malignant tumors of the female genital organs.
In Poland, ovarian cancer was ranked sixth at the incidence of cancer in women. Data from
the National Council (National Cancer Registry) reported that it represented in 2014 4.6% of
cases of cancer of the female population in Poland. [24, 25]
This means that every year in our country are recognized by about 2700 new cases per 100
thousand. women.
Taking  into  account  deaths  from gynecological  cancers  localized  in  the  first  place.  The
mortality rate of women in 2014. A cancer of the ovary was 5.8%, [20, 24].
Research carried out in the world shows that there is still a slow increase in the incidence of
ovarian cancer.
At the time of diagnosis of ovarian cancer in 70% of cases, the disease is already very large.
The location of the body inside the abdomen hinders proper and early diagnosis.
The decisive factor in the treatment and survival of a patient's age and severity.
For women suffer from ovarian cancer at any age, but the escalation of cases occur in the
interval between 40 and 70 years of age. Very rare disease before age 30. [9]
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It was also noted that there is dependence on the race, the impact of environmental conditions
and  geographical  location.  Women  often  suffer  Caucasians,  African-American  population
less. Cancer often occurs in regions highly and less in countries with low socio-economic
status.
Etiology
Parent number of ovarian cancer originates from the epithelial cells covering the surface of
the  ovary.  It  is  a  mesodermal  epithelium,  which  originally  inlays  body  cavity  during
embryogenesis.
The term tumor is determined incorrectly burgeoning tissue, which nucleus may be one of
"bad"  cell  body.  The  resulting  cells  divide  uncontrollably  connected  to  the  wrong  their
differentiation.
Only cells that have a lifelong ability to divide and differentiate tumors may arise.
Ovarian surface cells  maintain this ability,  which becomes the cause of a huge variety of
histological ovarian tumors.
Mutations in genes that play an important role in the cell cycle causes the body loses control
over the processes of proliferation. [17]
Risk factors for ovarian cancer
Modern  medicine  proves  that  the  formation  of  ovarian  tumors  affecting  hormonal
interactions, genetic and environmental factors.
They identified many risk factors. Considered to be the most important:
 age
 sterility
 no pregnancies, and thus the lack of breast-feeding periods
 Multiple stimulation of ovulation in in vitro programs
 hormonal disorders in the form of hyperandrogenism and hiperstrogenism
 nikotynizm
 endometriosis
 state with a history of pelvic radiotherapy
 traveled cancer
 a history of endemic infection (influenza) parotitis (Mumps)
 exposure crystals talc
 diet low in vitamin A and D
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 high-fat diet leading to obesity. [7, 18]
The factors include genetic carriers of BRCA1, BRCA2, and genes associated with DNA
repair - MSH2 and MLH1.
Environmental  factors,  which presumably are involved in  tumorigenesis  is  a  lifestyle  and
nutrition.
In  countries  with  better  socioeconomic  conditions  diet  contains  a  lot  more  animal  fats.
Registered escalation of morbidity at the time of intensified consumption of red meat, which
contains dangerous to the health of polyunsaturated fatty acids. [23,24]
Among postmenopausal women low-fat diet may be a factor reducing the risk.
Research shows that people whose diet is rich in lactose, are also at increased risk. While at
the  same  time  they  are  affected  by  a  lack  of  the  enzyme  galactose  -  1  -
fosfourydylotransferazy.
Amongst the developed countries, only Japan has a low incidence rate, namely three cases per
100 thousand. population. [13,15]
Classical prognostic factors of ovarian tumors
Defined group of factors that estimate is important in predicting the course of the disease.
They bind tightly with the fixing of the optimal methods of treatment, classifying the patient
to the appropriate group prognosis and to determine survival.
For prognostic factors are counted:
 clinical stage FIGO (staging)
 the degree of histological differentiation (grading)
 histological type
 age and general condition of the patient
 applied to determine the degree of treatment and resulting cytoreduction
 the concentration of tumor markers
 the presence of genetic mutations [23]
Clinical stage
The most  important element is  the prognostic stage malignant  tumors of the ovary FIGO
1988. - Table 1. This classification was based on the results of currently used diagnostic and
intraoperative assessment. [11]
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Table 1. Clinical division FIGO ovarian cancers [23]
FIGO classification of ovarian cancer
Stage I Tumor limited to the ovaries
IA Tumor limited to one ovary
IB Tumor limited to two ovaries
IC IA or IB in excess of the outer shell of the ovary or ascites fluid and
the presence of malignant cells
Stage II The disease limited to the pelvis
IIA Addressing the reproductive organ
IIB The involvement of other tissues within the pelvic cavity
IIC IIA or IIB in excess of the outer shell of the ovary or ascites fluid
and the presence of malignant cells
grade III The  disease  outside  the  pelvis  or  inguinal  lymph  nodes  or
retroperitoneal
IIIA
Changes microscopic tumor on the surface of abdominal peritoneal
IIIB Macroscopic change of diameter <2 cm
IIIC Macroscopic change in diameter> 2 cm IA or IB in excess of the
outer shell ovary or lymph nodes or inguinal inside the peritoneum
Stage IV Metastatic cancer - location outside the abdominal cavity.
If there is infiltration within the pleura, it must also be a positive
Pap smear; liver metastases
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Based on the  FIGO stage  five-year  survival  period  of  women  with  ovarian  cancer  is  as
follows.
1. degree 72%
2. degree 46.3%
3. degree 17.2%
4. level of 4.8%
The degree of histological differentiation (grading)
Histopathological assessment of the degree of differentiation is another feature of prognostic.
It is the most promising form of cancer with high histological grade defined as the degree of
G1.
There are three degrees of histological differentiation.
 GX - the level of diversity possible to determine the
 G1 - tumors with a high degree of differentiation
 G2 - tumors up to 50% undifferentiated cells
 G3 - tumors whose cells are undifferentiated cells exceed 50%. 
The longest survival observed in patients with highly diverse types [23].
histological Classification
By far the largest number of malignant ovarian tumors derived from epithelial ovarian outer
layer, namely, 55%.
Change the original structure may have benign tumors. Sometimes, however, that with the
passage of time shall be subject to the local proliferation of creating the character limit.
Today, the existing divisions of ovarian tumors based on histogenesis have been developed by
WHO.
The division shows the following:
I. Cancers of the surface epithelium and stroma
 benign epithelial tumors
 tumors of borderline malignancy
 cancer
- serous
- mucous
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- endometrioid
- transitional cell (Brenner tumors) [17, 18]
II. Tumors of the strings sex and ovarian stroma (Gonadal)
-user fibrosarcoma 
-Sertoli cells and Leydig
-cell lipid
III. Germ cell tumors (germ) - germinoma
-Rake embryonic
-nabłoniak chorionic
-potworniak (mature, immature solid, cystic, jednolistkowy)
- mixed germ
IV. Mixed tumors germinalno - Gonadal
-gonadoblastoma
V. Tumors classified
VI. For non-specific tumors gonad
VII. Metastatic tumors, which constitute about 15%
Table 2. The frequency of metastasis from other tumors to the ovary tumors [18]
The original location of the tumor The frequency of metastases to theovary
Stomach 50 - 80%
Fallopian tube 50%
Nipple 25 - 30%
Metastasis from the second ovary 25%
Large intestine 15 - 22%
Age and general condition of the patient
A very important prognostic factor is the age of the sick woman. Peak incidence for about and
postmenopausal.  Gonads  no  longer  perform  its  physiological  function,  therefore  their
operation irregularities are noticeable.
No specific cause of symptoms is late diagnosis of the disease. In women, young recognition
occurs  most  often  when  the  degree  of  clinical  severity  and  stage  is  lower  than  the
histopathological differentiation is higher.
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Research shows that older patients are even worse bad prognosis for survival. Decreases with
age the body's resistance and cardio defense mechanisms. Patients of advanced age often have
other accompanying diseases such as hypertension, obesity often, circulatory failure.
In the early stages of ovarian tumors do not produce characteristic symptoms. Non-specific
symptoms may indicate disease processes not associated with the gonads. For this reason,
patients report only when the severity of the disease is very high. Underway in the pelvic
tumor proliferative process becomes a cause of the following symptoms:
abdominal pain and sacral bloating, constipation, indigestion, feeling of fullness
 Disorder in passing urine and stool
 nausea, vomiting, loss of appetite
 swelling of the lower limbs
 loss or weight gain
 Abdominal distension
Patients  with  very  high  severity  process  cancers  characterized  emaciated  silhouettes
disproportionately  large  abdominal  circumference  and  specific,  stringent  so-called  facial
features. The sick, the less proposed to "aggressive" treatment. [8.11]
Hereditary cancer syndromes
One of the most  important elements  of the risk of developing ovarian cancer is  a family
history  of  this  disease.  Modern  research  has  shown that  5  -  15% of  ovarian  tumors  are
responsible for gene mutations.
Condition the genes of cancer, ovarian and breast cancer genes BRCA1 and BRCA2. Their
mutation is found in 90 - 95% of all hereditary cancer syndromes.
In the general population of women the risk of ovarian cancer is  estimated at  1.6%. The
presence of the BRCA1 mutation increases the risk to 16 - 46%. In the case of mutations in
the BRCA2 gene is increased to 11 - 27%. Women who carry these mutations are getting on
average about ten years earlier.
In families where there are many generations of ovarian cancer increases the risk of getting
fifty. [20, 21]
Modern medicine describes three sets of hereditary tumor site j aj media.
1. Syndrome hereditary  breast  cancer  and  ovarian  cancer  (HBOC- Hereditary  Breast
Cancer Ovarian). It comprises about 75-90%, and is associated with the BRCA1 gene
mutation.
2. Site-specific  assembly  hereditary  ovarian  carcinoma  (HOC-Hereditary  Ovarian
Cancer). It amounts to about 5%, and is associated with a mutation in the gene BRCA
1 and 2.
3. Lynch  syndrome  (Lynch  Syndrome,  HNPCC-  Nonpolyposis  Hereditary  Colorectal
Cancer). Of about 2%, and is associated with a mutation of MSH2, MLH1. This group
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includes cancer and colon adenocarcinoma (endometrium, small intestine,  stomach,
ovary, urinary tract, bile ducts). [1, 2, 12, 15, 18, 20, 21]
Prevention of ovarian tumors
Preventive  actions  in  the  field  of  ovarian  cancer  are  constantly  a  huge  challenge  for
organizations engaged in health promotion programs.
Epidemiological studies have shown that the fight against ovarian cancer in Poland and in the
world still brings unsatisfactory results. It conducted a series of studies aimed at identifying
new methods to detect cancer in early stages.
Unfortunately, there is still a method that would be highly sensitive and specific to meet the
criterion of effective screening test according to WHO standards.
The prevention of tumors, there are three stages of prevention: primary prevention, secondary
and tertiary.
In primary prevention  should educate women about  the risk factors  for  the disease.  It  is
important to encourage a healthy lifestyle manifested attention to physical activity, diet and
regular medical examination.
Women who were at special risk groups should be offered and be able to perform regular
diagnostic tests.
Secondary  prevention  is  aimed  at  the  early  detection  of  ovarian  cancer  in  the  form  of
screening.
Despite specific efforts of the medical community still fails to extract a single test that ovarian
tumors facilitates a high sensitivity and specificity.
Screening  of  tumors  of  the  ovary  include  intelligence,  gynecological  examination,
transvaginal ultrasonography and assessment of the concentration of CA 125 antigen.
Activities under prevention of ovarian tumors are still difficult social problem and requires
ongoing research efforts to enable early diagnosis. [3, 13, 14]
Summary
Malignant neoplasm of the ovary, not without reason, is called the "silent killer". Clinical
symptoms in the early stages of the disease are nonspecific, which significantly delays the
diagnosis.  About  70% of  patients  report  to  the  doctor  III  and stage  IV.  Accordingly,  the
prognosis is poor and the very high mortality rate.
Disturbing  epidemiological  data  and  diagnostic  difficulties  make  it  modern  medicine
constantly strives to develop effective methods for diagnosis and treatment of ovarian tumors.
Research has shown that carcinogenic processes in ovarian tumors arise from the interaction
of hormonal, genetic and environmental factors.
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A large group of cases,  is  associated with genetic predisposition namely mutations  in the
genes BRCA1 and BRCA2. Accordingly, it is important to isolate the population from the risk
groups and take their programs regular diagnostic tests.
There is still no sensitive and specific screening methods that allow early detection of ovarian
cancer.  Taking  control  gynecological,  through  vaginal  ultrasound  examination  and
determination of concentration of the antigen CA 125 is the primary form of screening.
Ovarian cancer has long been a topic of special interest to the medical community, raising
standards for early detection and treatment of this disease.
For ovarian cancer medical community has long been a topic of special interest to improve the
standards of early detection and treatment of this diseas.
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